Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + Radiotherapy in Advanced Liver Cancer
NCT04523662Phase 2Unknown
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Beijing Tsinghua Changgung Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04523662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523662.